




FIG. 1




FIG. 2




FIG. 3

BCMA expression in target cells




FIG. 4

BCMA-1 shows target-dependent expansion and maintains activity after repeated stimulation




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10

Rituximab depletes CAR T cells and
abrogates antitumor activity




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18





FIG. 19



DL = dose level

DL1 = 40×10^6 viable CAR+ cells

DL2 = 160×10^6 viable CAR+ cells

DL3 = 320×10^6 viable CAR+ cells

ID = intermediate dose. A dose level between DL1 and DL3 if toxicity observed with DL3 or to determine a lower dose that is efficacious.

DL4 = 480×10^6 viable CAR+ cells. To be done if inadequate efficacy parameters are seen in DL3.

* If safety is maintained in the previous cohort then the dose escalation will move to the next cohort shown by the arrow.

If multiple cohorts are open at the same time, patients will be assigned to a specific cohort based on practical consideration.

§ DL4 or ID or neither.

FIG. 20




FIG. 21